Eisai’s Lemborexant Sleep Aid Lemborexant Filed for NMPA Approval in China
The China Center for Drug Evaluation (CDE) website has indicated that Japan-based Eisai (TYO: 4523)...
Company
Astellas Pharma Appoints Zhao Ping as Chairman of China Operations
Effective January 15, 2024, Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has appointed...
Keylights Biotechnology Raises $14 Million in Series B to Expand IVD Instrument Range
Keylights Biotechnology Co., Ltd., a leading in vitro diagnostic (IVD) instruments manufacturer headquartered in Shenzhen,...
Joincare Pharmaceutical’s Partner Fermion Gets NMPA Green Light for Pain Drug Clinical Study
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced that...
Gansu Deshengtang Partners with RELEX Solutions to Enhance Supply Chain Efficiency
Gansu Deshengtang Medical Science and Technology Group Co., Ltd, a prominent Chinese healthcare group, has...
GSK Secures Second Indication Approval for Nucala in China for Severe Eosinophilic Asthma
GSK plc (NYSE: GSK) has received approval for a second indication in China for its...
China Resources Medical Laboratory Partners with Qlife Lab for Comprehensive Mass Spectrometry Solutions
China Resources Medical Holdings Company Limited’s subsidiary, China Resources (Guangdong) Medical Laboratory Co., Ltd, has...
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...
Junshi Biosciences Regains Global Rights to JS006 as Coherus Terminates Licensing Agreement
Junshi Biosciences (HKG: 1877; SHA: 688180), based in Suzhou, has announced the termination of its...
Amgen Licenses XeriJect Technology from Xeris Biopharma for Subcutaneous Tepezza Development
Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for...
Eli Lilly Secures NMPA Approval for Emgality as Preventive Migraine Treatment in China
Eli Lilly (NYSE: LLY) has received marketing approval from the National Medical Products Administration (NMPA)...
C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials
C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...
Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies
Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company...
Henlius Biotech Secures Exclusive Rights to Sermonix’s Lasofoxifene for Breast Cancer Treatment in China
Shanghai Henlius Biotech Inc. (HKG: 2696) has entered into a partnership and licensing agreement with...
GenFleet’s SLS009 Receives Fast-Track and Orphan Drug Designations from U.S. FDA for Lymphoma and Leukemia
Shanghai-based biotech GenFleet Therapeutics announced that its CDK9 inhibitor, SLS009 (GFH009), has received fast-track and...
GSK’s Acquisition of Aiolos Bio Bolsters Respiratory Medicine Portfolio with AIO-001
UK pharmaceutical giant GSK plc (LON: GSK) has announced a deal to acquire Aiolos Bio,...
WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China
WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization...
Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Bangladesh
Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical device company, has announced that...
Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China
Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets...
Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration
The US Food and Drug Administration (FDA) has accepted for priority review a filing from...